TY - JOUR
T1 - Performance of depression rating scales in patients with chronic kidney disease
T2 - an item response theory-based analysis
AU - Toups, Marisa
AU - Carmody, Thomas
AU - Trivedi, Madhukar H.
AU - Rush, A. John
AU - Hedayati, S. Susan
N1 - Funding Information:
Funding: This work was supported by a Veterans Affairs MERIT grant (CX000217–01) and a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) (R01DK085512) (Susan Hedayati, M.D.), the NIMH (K23MH104768) (Marisa Toups, MD), the Hersh Foundation and the Center for Depression Research and Clinical Care (Madhukar H. Trivedi, M.D). The views expressed here are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the NIH.
Funding Information:
Financial Disclosures: A. John Rush, M.D. has received consulting fees from Brain Resource Ltd., H. Eli Lilly, Lundbeck A/S, Medavante, Inc.; National Institute of Drug Abuse, Santium Inc.,Takeda USA,; speaking fees from the University of California at San Diego, Hershey Penn State Medical Center, and the American Society for Clinical Psychopharmacology; royalties from Guilford Publications and the University of Texas Southwestern Medical Center; a travel grant from CINP and research support from Duke-National University of Singapore. Madhukar H. Trivedi, MD is or has been an advisor/consultant and received fees from: Alkermes, AstraZeneca, Cerecor, Eli Lilly & Company, Lundbeck, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., SHIRE Development and Takeda. Marisa Toups, MD has received fees from Otsuka Pharmaceuticals.
Publisher Copyright:
© 2016
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Objective Because there is overlap between somatic symptoms of depression and symptoms of chronic kidney disease (CKD), it is unclear if self-reported depression rating scales can be used accurately in predialysis CKD patients, especially if CKD and other comorbidities are symptomatic. We assessed the performance of two depression scales — the Beck Depression Inventory (BDI) and the Quick Inventory of Depression Symptomatology (QIDS-SR16) — by CKD stage, diagnosis of diabetes and total medical comorbidity burden — using item response theory (IRT) in a sample of 272 predialysis CKD patients. Methods We performed IRT by low versus high CKD stage, diabetes versus no diabetes and high (>3 diagnoses) versus low medical comorbidity burden. Results IRT models of each rating scale were affected in a limited way by CKD stage, diabetes and medical comorbidity burden. Sleep disturbances on the QIDS-SR16 were more discriminatory for depression in diabetics and those with high comorbidity burden. Pessimism and guilt from the BDI compared to QIDS-SR16 were more discriminatory of depression in the high CKD and high comorbidity groups, respectively. Conclusions Overall item differences were modest, and chronic disease severity by CKD stage, diabetes mellitus or other medical comorbidities did not appreciably contribute to differences in scale performance.
AB - Objective Because there is overlap between somatic symptoms of depression and symptoms of chronic kidney disease (CKD), it is unclear if self-reported depression rating scales can be used accurately in predialysis CKD patients, especially if CKD and other comorbidities are symptomatic. We assessed the performance of two depression scales — the Beck Depression Inventory (BDI) and the Quick Inventory of Depression Symptomatology (QIDS-SR16) — by CKD stage, diagnosis of diabetes and total medical comorbidity burden — using item response theory (IRT) in a sample of 272 predialysis CKD patients. Methods We performed IRT by low versus high CKD stage, diabetes versus no diabetes and high (>3 diagnoses) versus low medical comorbidity burden. Results IRT models of each rating scale were affected in a limited way by CKD stage, diabetes and medical comorbidity burden. Sleep disturbances on the QIDS-SR16 were more discriminatory for depression in diabetics and those with high comorbidity burden. Pessimism and guilt from the BDI compared to QIDS-SR16 were more discriminatory of depression in the high CKD and high comorbidity groups, respectively. Conclusions Overall item differences were modest, and chronic disease severity by CKD stage, diabetes mellitus or other medical comorbidities did not appreciably contribute to differences in scale performance.
KW - Assessment
KW - Chronic kidney disease
KW - Comorbidity
KW - Depression
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=84982693438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982693438&partnerID=8YFLogxK
U2 - 10.1016/j.genhosppsych.2016.07.005
DO - 10.1016/j.genhosppsych.2016.07.005
M3 - Article
C2 - 27638974
AN - SCOPUS:84982693438
SN - 0163-8343
VL - 42
SP - 60
EP - 66
JO - General Hospital Psychiatry
JF - General Hospital Psychiatry
ER -